SecBot SecBot
8-K ·Filed Sep 2, 2026

INBS

INTELLIGENT BIO SOLUTIONS INC.
BEARISH
Impact 7/10
Horizonweeks Processed1mo ago SEC0001493152-26-041253
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

The $5M PIPE at a $2.455/share purchase price is highly dilutive for a $7M market cap company. Expect immediate downward pressure as shares are issued and as warrants overhang the market, especially the two tranches of five-year warrants at $2.33. Monitor the stock for a potential drop below the placement price as investors price in the dilution. The shareholder meeting requirement for Series N-2 warrants introduces event risk in 120 days — failure could force a renegotiation.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d
INBS ▼ -27.83% at T+20d
SHORT call ✓ call won +27.83% · α vs SPY +26.64% · entry $2.30 → $1.66
Next anchor: T+60d in 4w
Latest observation: T+35 +33.23% FF3 residual α
Entry = T+0 close
Sep 2, 2026
via day close
T+1d
-3.04%
call +3.04% · α +2.66%
$2.23
settled 8w ago
T+5d
-7.39%
call +7.39% · α +6.24%
$2.13
settled 7w ago
T+20d
-27.83%
call +27.83% · α +26.64%
$1.66
settled 26d ago
T+60d
Pending
in 4w

Price Chart

Loading chart...

Executive Summary

Intelligent Bio Solutions Inc. entered into a securities purchase agreement on August 31, 2026, to raise approximately $5.0 million ($4,999,998) through the sale of common stock, pre-funded Series M warrants (exercise price $0.01/share), and Series N-1 and N-2 warrants (exercise price $2.33/share). The combined issuance of shares and warrants will cause substantial dilution to existing common stockholders (estimated at 70%+ given the $7M market cap), with the potential for even greater dilution if all warrants (including those with a five-year term) are exercised. Proceeds are earmarked for working capital.

Key Financial Metrics

Offering Size
$5.0M

Key Facts

  • Aggregate offering size of $4,999,998 in shares, Series N-1 Warrants, and Series N-2 Warrants.
  • Per Share Purchase Price set at $2.455; Series N-1/N-2 Warrants exercisable at $2.33 per share for five years post-registration effectiveness.
  • Series M Pre-Funded Warrants priced at $2.445 ($2.455 minus $0.01) with a nominal exercise price of $0.01/share.
  • Placement agent warrants issued to Ladenburg Thalmann with exercise price of $3.06875 per share.
  • Company must seek shareholder approval to issue Series N-2 Warrant Shares (triggering Nasdaq rules).
  • Company is restricted from variable-rate transactions for six months after closing and from most equity issuances for 60 days post-effectiveness of the resale registration statement.

Financial Impact

Approximately $5.0 million gross proceeds raised via private placement; shares and warrants represent roughly 70%+ dilution of current market cap ($7M).

share countdilutionstock price (due to overhang from warrants)

Risk Factors

  • Extreme dilution: issuance of shares and warrants could increase the float by 100%+ relative to current shares outstanding.
  • Warrant overhang: two sets of five-year warrants (100% of share+pre-funded warrant coverage each) provide a significant supply overhang if the stock rallies toward $2.33.
  • Nasdaq compliance risk: capital raise suggests potential listing requirement issues; reverse stock split within one year is prohibited unless needed for listing.
  • Shareholder vote risk: failure to obtain approval for Series N-2 warrants within 120 days could create contractual instability.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-041253
Exhibit: ex10-2.htm0001493152-26-041253
Exhibit: ex4-4.htm0001493152-26-041253
Exhibit: ex4-3.htm0001493152-26-041253
17 reports for INBS
Performance horizon
75% Hit rate @ T+20 3 of 4 directional calls Went positive at some point 3 of 4 best @ T+20▲ +43.43%Jul 23, 2026
Filters
Rows
Reports for INBS — sortable, filterable
TypeNow
Oct 21, 2026
5d ago
10-K/A
NEUTRAL ★ 3/10
$1.69awaiting T+20—$1.64 (−2.67%)
Oct 13, 2026
13d ago
8-K
NEUTRAL ★ 2/10
$1.45awaiting T+20—$1.64 (+13.10%)
Sep 24, 2026
4w ago
EFFECT
BEARISH ★ 5/10
$1.71 $1.69▲ +1.46%▲ +1.04%$1.64 (+4.09%)
Sep 15, 2026
5w ago
S-3
NEUTRAL ★ 3/10
$1.97 $1.48▼ −24.87%▼ −28.05%$1.64 (−16.75%)
Sep 11, 2026
6w ago
8-K
NEUTRAL ★ 2/10
$2.07 $1.51▼ −27.05%▼ −29.32%$1.64 (−20.77%)
Sep 9, 2026
6w ago
8-K
BULLISH ★ 6/10
$2.24 $1.59▼ −29.02%▼ −30.96%$1.64 (−26.79%)
Sep 2, 2026
7w ago
8-K
BEARISH ★ 7/10
$2.30 $1.66▲ +27.83%▲ +26.64%$1.64 (+28.70%)
Aug 19, 2026
9w ago
8-K
NEUTRAL ★ 5/10
$2.67 $2.05▼ −23.22%▼ −21.70%$1.64 (−38.58%)
Aug 19, 2026
9w ago
Press Release
BEARISH ★ 5/10
$2.67 $2.05▲ +23.22%▲ +21.70%$1.64 (+38.58%)
Aug 17, 2026
10w ago
Press Release
NEUTRAL ★ 4/10
$3.37 $2.05▼ −39.17%▼ −37.19%$1.64 (−51.34%)
Showing 10 of 17

US Market Status

Market Closed — Opens in 7h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026